Logo image of CLLS

CELLECTIS - ADR (CLLS) Stock Fundamental Analysis

NASDAQ:CLLS - Nasdaq - US15117K1034 - ADR - Currency: USD

1.44  +0.06 (+4.35%)

Fundamental Rating

3

Overall CLLS gets a fundamental rating of 3 out of 10. We evaluated CLLS against 568 industry peers in the Biotechnology industry. The financial health of CLLS is average, but there are quite some concerns on its profitability. While showing a medium growth rate, CLLS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CLLS had negative earnings in the past year.
In the past year CLLS had a positive cash flow from operations.
CLLS had negative earnings in each of the past 5 years.
CLLS had negative operating cash flow in 4 of the past 5 years.
CLLS Yearly Net Income VS EBIT VS OCF VS FCFCLLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

CLLS has a better Return On Assets (-14.12%) than 83.45% of its industry peers.
The Return On Equity of CLLS (-41.34%) is better than 69.89% of its industry peers.
Industry RankSector Rank
ROA -14.12%
ROE -41.34%
ROIC N/A
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
CLLS Yearly ROA, ROE, ROICCLLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

CLLS has a better Gross Margin (4.64%) than 71.83% of its industry peers.
The Profit Margin and Operating Margin are not available for CLLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 4.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLLS Yearly Profit, Operating, Gross MarginsCLLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

4

2. Health

2.1 Basic Checks

CLLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CLLS has more shares outstanding
CLLS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CLLS has been reduced compared to a year ago.
CLLS Yearly Shares OutstandingCLLS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CLLS Yearly Total Debt VS Total AssetsCLLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -1.09, we must say that CLLS is in the distress zone and has some risk of bankruptcy.
CLLS has a better Altman-Z score (-1.09) than 60.39% of its industry peers.
The Debt to FCF ratio of CLLS is 4.88, which is a neutral value as it means it would take CLLS, 4.88 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 4.88, CLLS belongs to the best of the industry, outperforming 93.49% of the companies in the same industry.
A Debt/Equity ratio of 0.65 indicates that CLLS is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.65, CLLS is not doing good in the industry: 75.88% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF 4.88
Altman-Z -1.09
ROIC/WACCN/A
WACC6.27%
CLLS Yearly LT Debt VS Equity VS FCFCLLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 1.73 indicates that CLLS should not have too much problems paying its short term obligations.
CLLS's Current ratio of 1.73 is on the low side compared to the rest of the industry. CLLS is outperformed by 79.23% of its industry peers.
A Quick Ratio of 1.73 indicates that CLLS should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.73, CLLS is not doing good in the industry: 78.17% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.73
Quick Ratio 1.73
CLLS Yearly Current Assets VS Current LiabilitesCLLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

CLLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 80.34%, which is quite impressive.
CLLS shows a strong growth in Revenue. In the last year, the Revenue has grown by 412.40%.
The Revenue has been growing by 16.44% on average over the past years. This is quite good.
EPS 1Y (TTM)80.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%111.43%
Revenue 1Y (TTM)412.4%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%662.06%

3.2 Future

Based on estimates for the next years, CLLS will show a very negative growth in Earnings Per Share. The EPS will decrease by -75.28% on average per year.
The Revenue is expected to grow by 30.02% on average over the next years. This is a very strong growth
EPS Next Y-235.09%
EPS Next 2Y-58.04%
EPS Next 3Y-75.28%
EPS Next 5YN/A
Revenue Next Year11.14%
Revenue Next 2Y-24.22%
Revenue Next 3Y24.63%
Revenue Next 5Y30.02%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CLLS Yearly Revenue VS EstimatesCLLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M 200M 250M
CLLS Yearly EPS VS EstimatesCLLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CLLS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLLS Price Earnings VS Forward Price EarningsCLLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, CLLS is valued cheaper than 98.42% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7.54
EV/EBITDA N/A
CLLS Per share dataCLLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A cheap valuation may be justified as CLLS's earnings are expected to decrease with -75.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-58.04%
EPS Next 3Y-75.28%

More info and screens

0

5. Dividend

5.1 Amount

CLLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELLECTIS - ADR

NASDAQ:CLLS (4/22/2025, 8:00:00 PM)

1.44

+0.06 (+4.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13 2025-03-13/amc
Earnings (Next)05-07 2025-05-07
Inst Owners20.91%
Inst Owner Change0%
Ins Owners3.88%
Ins Owner ChangeN/A
Market Cap144.42M
Analysts86.15
Price Target5.61 (289.58%)
Short Float %0.33%
Short Ratio0.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)82%
Min EPS beat(2)18.3%
Max EPS beat(2)145.69%
EPS beat(4)4
Avg EPS beat(4)73.41%
Min EPS beat(4)6.42%
Max EPS beat(4)145.69%
EPS beat(8)6
Avg EPS beat(8)27.22%
EPS beat(12)9
Avg EPS beat(12)23.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)108.7%
Min Revenue beat(2)55.84%
Max Revenue beat(2)161.56%
Revenue beat(4)4
Avg Revenue beat(4)91.56%
Min Revenue beat(4)50.31%
Max Revenue beat(4)161.56%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)8.07%
EPS NQ rev (3m)8.07%
EPS NY rev (1m)-18.23%
EPS NY rev (3m)1.88%
Revenue NQ rev (1m)19.78%
Revenue NQ rev (3m)19.78%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.96
P/FCF 7.54
P/OCF 6.28
P/B 1.1
P/tB 1.11
EV/EBITDA N/A
EPS(TTM)-0.35
EYN/A
EPS(NY)-1.17
Fwd EYN/A
FCF(TTM)0.19
FCFY13.26%
OCF(TTM)0.23
OCFY15.92%
SpS0.74
BVpS1.31
TBVpS1.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.12%
ROE -41.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 4.64%
FCFM 25.96%
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF 4.88
Debt/EBITDA N/A
Cap/Depr 19.36%
Cap/Sales 5.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.73
Quick Ratio 1.73
Altman-Z -1.09
F-Score7
WACC6.27%
ROIC/WACCN/A
Cap/Depr(3y)12.8%
Cap/Depr(5y)139.39%
Cap/Sales(3y)9.66%
Cap/Sales(5y)33.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)80.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%111.43%
EPS Next Y-235.09%
EPS Next 2Y-58.04%
EPS Next 3Y-75.28%
EPS Next 5YN/A
Revenue 1Y (TTM)412.4%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%662.06%
Revenue Next Year11.14%
Revenue Next 2Y-24.22%
Revenue Next 3Y24.63%
Revenue Next 5Y30.02%
EBIT growth 1Y35.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.35%
EBIT Next 3YN/A
EBIT Next 5Y-29.24%
FCF growth 1Y174.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y192.9%
OCF growth 3YN/A
OCF growth 5YN/A